The Use of Duloxetine for Cognition Improvement in Individuals With Mild Cognitive Impairment

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

19 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-01-31

Study Completion Date

2018-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether Cymbalta (duloxetine) is effective to improve cognition in individuals with Mild Cognitive Impairment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Assessment of Cognitive Functioning Before and After Treatment With Duloxetine

NCT00933439

Major Depressive Disorder

COMPLETED NA

Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder

NCT00105989

Depressive Disorder, Major

COMPLETED PHASE3

Study of Duloxetine in Elderly Patients With Major Depressive Disorder

NCT00062673

Depression Cognition

COMPLETED PHASE3

Duloxetine for the Treatment of Dysthymia

NCT00185575

Depressive Disorder

COMPLETED NA

Feasibility Study of Duloxetine in the Treatment of Depression in Patients With Traumatic Brain Injury

NCT01223001

Traumatic Brain Injury Depression

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The goal of this study is to conduct a proof of concept clinical trial using antidepressant therapy to improve cognition. This study will utilize a randomized, double blinded, placebo - controlled trial design. The investigators will recruit up to 100 patients. Patients will be screened multiple times to determine eligibility. Patients will be randomized into one of two study groups (placebo control group and Duloxetine group). Patients in the Duloxetine group will receive up to 60 mg of an FDA approved antidepressant, Duloxetine. Patients in the control group will receive a placebo that is the exact shape and size of the study drug. The patients, primary investigators, and research personnel will be blinded to the study condition. The investigators will designate one on-site personnel to serve as data and safety monitor. This person will not be blinded and will randomize patients to condition, work with the pharmacy, and can un-blind condition if necessary.

Potential patients will be invited to a screening visit. This visit is designed to ensure that the patients meet study criteria and that it is safe for them to participate in the study. The screening visit will consist of physical examinations, medical and psychological history, cognitive and functional testing, interviews, questionnaires, research/clinical venipuncture, and a meeting with the study doctor. If a patient is accepted to the trial, he/she will be expected to stay in the study for a minimum of 6 months.

After the screening visit, the study team will meet to determine if the patient will continue to remain in the study. If a patient does remain in the study, he/she will be invited to a randomization visit. Patients will be randomized into either the Duloxetine group or the placebo control group. The data and safety monitor will use a randomization software. This program allows the researcher to enter in the number of subject, and condition, and will generate a table of randomly assigned patients to condition. The patients and study personnel will be blinded to the condition. The data safety monitor will randomly assign patients to condition and work with the pharmacy to properly label the study drugs. Only the data monitoring personnel will be un-blinded and will generate the table of random numbers. After randomization, patients will undergo vitals, interviews, testing, and the study drug will be dispensed to them. First dosage will consist of 30 mg of Duloxetine or placebo, and the participant will be asked to take the first dose at this visit.

Patients will be invited to a 2 week post randomization visit that will consist of a meeting with the study doctor to discuss concerns or side effects. Medication dosage will be raised to 60 mg of Duloxetine or placebo.

Patients will be seen monthly for the next three months. During these visits the patients will receive their study drugs, have their vital signs measured, and be questioned about adverse events or any health changes.

One month later, patients will have a follow up visit. This visit will consist of follow up interview and neuropsychological testing, clinical/research blood draw, and study doctor visit. This will be the final data collection study visit. The investigators will reduce the dosage of the study drug to 30 mg at this visit. The patients will be instructed that the investigators will be weaning off the study drug at this time.

The last study visit will be 2 weeks after the follow-up visit. This visit will consist of a study debriefing with the patient. At this visit the investigators will discontinue the study drug. The investigators will also arrange for the data monitoring personnel to un-blind the study at this time. No data will be collected at this visit. The participants will be informed of whether or not they were on the study drug or placebo. If a patient in the study drug group wishes to remain on Duloxetine, the patients will be advised to discuss it with their personal healthcare provider.

Research data will be stored and managed in a secure manner following NIH guidelines and according to state and institutional policies. Only authorized key personnel shall have access to research related documents. All personnel will be properly trained and supervised regarding the management and handling of confidential materials. The Principal Investigator assumes full responsibility for such training, supervision, and conduct.

All data will be stored in locked file cabinets behind locked doors in the PIs research laboratory until entered into the research database. Computer-based data entry will not require hard copy storage. All data collected via paper-pencil will be double entered into the research database by independent research assistants and results checked for quality control (QC). Once all hard copies have been entered, they will be scanned into PDF files for storage; all hard copies will be shredded. We will maintain the original signed consent forms for our records (these documents will not be shredded and will be kept in a locked file cabinet). Electronic scanned files will be stored in password protected files for security purposes. All discrepancies will be validated by chart review before the data are merged into the larger database. The database will contain item-level data to avoid the need for subsequent data entry processes as potential data analyses arise. Periodic QC checks will be conducted by our IT personnel and provided to the PI. All electronic records will be maintained on password protected computers behind locked doors in the PI's office space. All files will be backed up weekly on an independent external hard drive, which is also password protected.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Mild Cognitive Impairment Depression

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Duloxetine group

Active drug group

Group Type EXPERIMENTAL

Duloxetine

Intervention Type DRUG

Duloxetine 30 mg per day for 2 weeks. Duloxetine 60 mg per day for 4 months. Duloxetine 30 mg per day for 2 weeks.

Placebo group

Inactive drug group

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo 30 mg per day for 2 weeks. Placebo 60 mg per day for 4 months. Placebo 30 mg per day for 2 weeks.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Duloxetine

Duloxetine 30 mg per day for 2 weeks. Duloxetine 60 mg per day for 4 months. Duloxetine 30 mg per day for 2 weeks.

Intervention Type DRUG

Placebo

Placebo 30 mg per day for 2 weeks. Placebo 60 mg per day for 4 months. Placebo 30 mg per day for 2 weeks.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Cymbalta Avicel

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female, age 50 and up.
* Female participants must be post-menopausal for at least two consecutive years.
* Health and Aging Brain Study participant, who provided consent for re-contact
* Diagnosis of MCI (by Health and Aging Brain Study Consensus Review).
* Has an elevated DepE score (2 or more). This is calculated by summing scores for five items (Items 14, 16, 17,25 \&26) on the Geriatric Depression Scale.

Exclusion Criteria

* Inability to provide informed consent by self or by proxy.
* Pregnant or breast feeding women
* Uncontrolled narrow angle glaucoma
* Known hypersensitivity to duloxetine.
* Participation in a Clinical Trial in the last three months.
* Other psychiatric disorder like bipolar disorder, schizophrenia, or dementia.
* Use of antidepressants, anti-psychotics, and mood stabilizers.
* History of stroke.

Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No